Robert E Landry Insider Trading for April 2020
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Robert E Landry.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Overview of insider trading of Robert E Landry for April 2020.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 12,500 | 3,408,750 | 19,000 | |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 4,000 | 1,090,800 | 31,500 | |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 573.40 | 320 | 183,488 | 24,373 | 24.7 K to 24.4 K (-1.30 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 572.42 | 64 | 36,635 | 24,693 | 24.8 K to 24.7 K (-0.26 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 571.65 | 114 | 65,168 | 24,757 | 24.9 K to 24.8 K (-0.46 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 569.22 | 66 | 37,569 | 24,871 | 24.9 K to 24.9 K (-0.26 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 568.11 | 126 | 71,582 | 24,937 | 25.1 K to 24.9 K (-0.50 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 567.76 | 114 | 64,725 | 25,063 | 25.2 K to 25.1 K (-0.45 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 566.44 | 944 | 534,719 | 25,177 | 26.1 K to 25.2 K (-3.61 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 565.52 | 902 | 510,099 | 26,121 | 27 K to 26.1 K (-3.34 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 564.76 | 340 | 192,018 | 27,023 | 27.4 K to 27 K (-1.24 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 563.74 | 225 | 126,842 | 27,363 | 27.6 K to 27.4 K (-0.82 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 562.71 | 35 | 19,695 | 27,588 | 27.6 K to 27.6 K (-0.13 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 12,500 | 3,408,750 | 19,000 | |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 555.82 | 9,250 | 5,141,335 | 27,623 | 36.9 K to 27.6 K (-25.09 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 4,000 | 1,090,800 | 31,500 | |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 12,500 | 3,408,750 | 36,873 | 24.4 K to 36.9 K (+51.29 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 573.40 | 320 | 183,488 | 24,373 | 24.7 K to 24.4 K (-1.30 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 565.77 | 44 | 24,894 | 24,373 | 24.4 K to 24.4 K (-0.18 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 572.42 | 64 | 36,635 | 24,693 | 24.8 K to 24.7 K (-0.26 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 563.63 | 66 | 37,200 | 24,417 | 24.5 K to 24.4 K (-0.27 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 571.65 | 114 | 65,168 | 24,757 | 24.9 K to 24.8 K (-0.46 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 562.77 | 33 | 18,571 | 24,483 | 24.5 K to 24.5 K (-0.13 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 569.22 | 66 | 37,569 | 24,871 | 24.9 K to 24.9 K (-0.26 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 561.96 | 92 | 51,700 | 24,516 | 24.6 K to 24.5 K (-0.37 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 568.11 | 126 | 71,582 | 24,937 | 25.1 K to 24.9 K (-0.50 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 560.31 | 232 | 129,992 | 24,608 | 24.8 K to 24.6 K (-0.93 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 567.76 | 114 | 64,725 | 25,063 | 25.2 K to 25.1 K (-0.45 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 559.25 | 155 | 86,684 | 24,840 | 25 K to 24.8 K (-0.62 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 566.44 | 944 | 534,719 | 25,177 | 26.1 K to 25.2 K (-3.61 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 558.63 | 89 | 49,718 | 24,995 | 25.1 K to 25 K (-0.35 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 565.52 | 902 | 510,099 | 26,121 | 27 K to 26.1 K (-3.34 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 556.43 | 33 | 18,362 | 25,084 | 25.1 K to 25.1 K (-0.13 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 564.76 | 340 | 192,018 | 27,023 | 27.4 K to 27 K (-1.24 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 553.85 | 62 | 34,339 | 25,117 | 25.2 K to 25.1 K (-0.25 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 563.74 | 225 | 126,842 | 27,363 | 27.6 K to 27.4 K (-0.82 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 551.38 | 55 | 30,326 | 25,179 | 25.2 K to 25.2 K (-0.22 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 562.71 | 35 | 19,695 | 27,588 | 27.6 K to 27.6 K (-0.13 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 550.00 | 3 | 1,650 | 25,234 | 25.2 K to 25.2 K (-0.01 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 555.82 | 9,250 | 5,141,335 | 27,623 | 36.9 K to 27.6 K (-25.09 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 548.99 | 61 | 33,488 | 25,237 | 25.3 K to 25.2 K (-0.24 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 12,500 | 3,408,750 | 36,873 | 24.4 K to 36.9 K (+51.29 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 542.25 | 33 | 17,894 | 25,298 | 25.3 K to 25.3 K (-0.13 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 565.77 | 44 | 24,894 | 24,373 | 24.4 K to 24.4 K (-0.18 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 540.70 | 33 | 17,843 | 25,331 | 25.4 K to 25.3 K (-0.13 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 563.63 | 66 | 37,200 | 24,417 | 24.5 K to 24.4 K (-0.27 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 529.79 | 3,009 | 1,594,138 | 25,364 | 28.4 K to 25.4 K (-10.61 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 562.77 | 33 | 18,571 | 24,483 | 24.5 K to 24.5 K (-0.13 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 4,000 | 1,090,800 | 28,373 | 24.4 K to 28.4 K (+16.41 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 561.96 | 92 | 51,700 | 24,516 | 24.6 K to 24.5 K (-0.37 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 560.31 | 232 | 129,992 | 24,608 | 24.8 K to 24.6 K (-0.93 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 559.25 | 155 | 86,684 | 24,840 | 25 K to 24.8 K (-0.62 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 558.63 | 89 | 49,718 | 24,995 | 25.1 K to 25 K (-0.35 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 556.43 | 33 | 18,362 | 25,084 | 25.1 K to 25.1 K (-0.13 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 553.85 | 62 | 34,339 | 25,117 | 25.2 K to 25.1 K (-0.25 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 551.38 | 55 | 30,326 | 25,179 | 25.2 K to 25.2 K (-0.22 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 550.00 | 3 | 1,650 | 25,234 | 25.2 K to 25.2 K (-0.01 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 548.99 | 61 | 33,488 | 25,237 | 25.3 K to 25.2 K (-0.24 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 542.25 | 33 | 17,894 | 25,298 | 25.3 K to 25.3 K (-0.13 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 540.70 | 33 | 17,843 | 25,331 | 25.4 K to 25.3 K (-0.13 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 529.79 | 3,009 | 1,594,138 | 25,364 | 28.4 K to 25.4 K (-10.61 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 4,000 | 1,090,800 | 28,373 | 24.4 K to 28.4 K (+16.41 %) |
| Apr 16 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 3,500 | 954,450 | 35,500 | |
| Apr 16 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 525.30 | 2 | 1,051 | 24,373 | 24.4 K to 24.4 K (-0.01 %) |
| Apr 16 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 520.36 | 130 | 67,647 | 24,375 | 24.5 K to 24.4 K (-0.53 %) |
| Apr 16 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 519.58 | 76 | 39,488 | 24,505 | 24.6 K to 24.5 K (-0.31 %) |
| Apr 16 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 518.31 | 287 | 148,755 | 24,581 | 24.9 K to 24.6 K (-1.15 %) |
| Apr 16 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 517.84 | 304 | 157,423 | 24,868 | 25.2 K to 24.9 K (-1.21 %) |
| Apr 16 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 516.89 | 54 | 27,912 | 25,172 | 25.2 K to 25.2 K (-0.21 %) |
| Apr 16 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 521.45 | 2,647 | 1,380,278 | 25,226 | 27.9 K to 25.2 K (-9.50 %) |
| Apr 16 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 3,500 | 954,450 | 27,873 | 24.4 K to 27.9 K (+14.36 %) |
| Apr 13 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 3,500 | 954,450 | 39,000 | |
| Apr 13 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 517.71 | 46 | 23,815 | 24,373 | 24.4 K to 24.4 K (-0.19 %) |
| Apr 13 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 512.58 | 31 | 15,890 | 24,419 | 24.5 K to 24.4 K (-0.13 %) |
| Apr 13 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 511.59 | 156 | 79,808 | 24,450 | 24.6 K to 24.5 K (-0.63 %) |
| Apr 13 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 510.43 | 143 | 72,991 | 24,606 | 24.7 K to 24.6 K (-0.58 %) |
| Apr 13 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 509.45 | 170 | 86,607 | 24,749 | 24.9 K to 24.7 K (-0.68 %) |
| Apr 13 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 508.54 | 115 | 58,482 | 24,919 | 25 K to 24.9 K (-0.46 %) |
| Apr 13 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 507.45 | 30 | 15,224 | 25,034 | 25.1 K to 25 K (-0.12 %) |
| Apr 13 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 506.24 | 38 | 19,237 | 25,064 | 25.1 K to 25.1 K (-0.15 %) |
| Apr 13 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 505.60 | 99 | 50,054 | 25,102 | 25.2 K to 25.1 K (-0.39 %) |
| Apr 13 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 508.25 | 2,672 | 1,358,044 | 25,201 | 27.9 K to 25.2 K (-9.59 %) |
| Apr 13 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 3,500 | 954,450 | 27,873 | 24.4 K to 27.9 K (+14.36 %) |
| Apr 08 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 3,000 | 818,100 | 42,500 | |
| Apr 08 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 502.81 | 2 | 1,006 | 24,373 | 24.4 K to 24.4 K (-0.01 %) |
| Apr 08 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 497.50 | 694 | 345,265 | 24,375 | 25.1 K to 24.4 K (-2.77 %) |
| Apr 08 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 499.95 | 2,304 | 1,151,885 | 25,069 | 27.4 K to 25.1 K (-8.42 %) |
| Apr 08 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 3,000 | 818,100 | 27,373 | 24.4 K to 27.4 K (+12.31 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 3,000 | 818,100 | 45,500 | |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 1,500 | 409,050 | 48,500 | |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 2,000 | 545,400 | 50,000 | |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 2,500 | 681,750 | 52,000 | |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 499.37 | 73 | 36,454 | 24,373 | 24.4 K to 24.4 K (-0.30 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 3,000 | 818,100 | 45,500 | |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 498.80 | 62 | 30,926 | 24,446 | 24.5 K to 24.4 K (-0.25 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 1,500 | 409,050 | 48,500 | |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 497.60 | 25 | 12,440 | 24,508 | 24.5 K to 24.5 K (-0.10 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 2,000 | 545,400 | 50,000 | |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 496.33 | 54 | 26,802 | 24,533 | 24.6 K to 24.5 K (-0.22 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 2,500 | 681,750 | 52,000 | |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 495.56 | 2 | 991 | 24,587 | 24.6 K to 24.6 K (-0.01 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 499.37 | 73 | 36,454 | 24,373 | 24.4 K to 24.4 K (-0.30 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 494.42 | 172 | 85,040 | 24,589 | 24.8 K to 24.6 K (-0.69 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 498.80 | 62 | 30,926 | 24,446 | 24.5 K to 24.4 K (-0.25 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 493.51 | 99 | 48,857 | 24,761 | 24.9 K to 24.8 K (-0.40 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 497.60 | 25 | 12,440 | 24,508 | 24.5 K to 24.5 K (-0.10 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 492.76 | 25 | 12,319 | 24,860 | 24.9 K to 24.9 K (-0.10 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 496.33 | 54 | 26,802 | 24,533 | 24.6 K to 24.5 K (-0.22 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 490.66 | 50 | 24,533 | 24,885 | 24.9 K to 24.9 K (-0.20 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 495.56 | 2 | 991 | 24,587 | 24.6 K to 24.6 K (-0.01 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 489.50 | 121 | 59,230 | 24,935 | 25.1 K to 24.9 K (-0.48 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 494.42 | 172 | 85,040 | 24,589 | 24.8 K to 24.6 K (-0.69 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 497.48 | 25 | 12,437 | 25,056 | 25.1 K to 25.1 K (-0.10 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 493.51 | 99 | 48,857 | 24,761 | 24.9 K to 24.8 K (-0.40 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 496.28 | 11 | 5,459 | 25,081 | 25.1 K to 25.1 K (-0.04 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 492.76 | 25 | 12,319 | 24,860 | 24.9 K to 24.9 K (-0.10 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 495.24 | 69 | 34,172 | 25,092 | 25.2 K to 25.1 K (-0.27 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 490.66 | 50 | 24,533 | 24,885 | 24.9 K to 24.9 K (-0.20 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 489.50 | 121 | 59,230 | 24,935 | 25.1 K to 24.9 K (-0.48 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 497.48 | 25 | 12,437 | 25,056 | 25.1 K to 25.1 K (-0.10 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 496.28 | 11 | 5,459 | 25,081 | 25.1 K to 25.1 K (-0.04 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 495.24 | 69 | 34,172 | 25,092 | 25.2 K to 25.1 K (-0.27 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 494.68 | 91 | 45,016 | 25,161 | 25.3 K to 25.2 K (-0.36 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 493.54 | 146 | 72,057 | 25,252 | 25.4 K to 25.3 K (-0.57 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 492.60 | 109 | 53,693 | 25,398 | 25.5 K to 25.4 K (-0.43 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 491.72 | 85 | 41,796 | 25,507 | 25.6 K to 25.5 K (-0.33 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 490.11 | 51 | 24,996 | 25,592 | 25.6 K to 25.6 K (-0.20 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 489.39 | 128 | 62,642 | 25,643 | 25.8 K to 25.6 K (-0.50 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 488.55 | 246 | 120,183 | 25,771 | 26 K to 25.8 K (-0.95 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 494.68 | 91 | 45,016 | 25,161 | 25.3 K to 25.2 K (-0.36 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 487.29 | 91 | 44,343 | 26,017 | 26.1 K to 26 K (-0.35 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 493.54 | 146 | 72,057 | 25,252 | 25.4 K to 25.3 K (-0.57 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 486.66 | 78 | 37,959 | 26,108 | 26.2 K to 26.1 K (-0.30 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 492.60 | 109 | 53,693 | 25,398 | 25.5 K to 25.4 K (-0.43 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 485.63 | 62 | 30,109 | 26,186 | 26.2 K to 26.2 K (-0.24 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 491.72 | 85 | 41,796 | 25,507 | 25.6 K to 25.5 K (-0.33 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 484.96 | 22 | 10,669 | 26,248 | 26.3 K to 26.2 K (-0.08 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 490.11 | 51 | 24,996 | 25,592 | 25.6 K to 25.6 K (-0.20 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 483.51 | 139 | 67,208 | 26,270 | 26.4 K to 26.3 K (-0.53 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 489.39 | 128 | 62,642 | 25,643 | 25.8 K to 25.6 K (-0.50 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 492.05 | 2,317 | 1,140,080 | 26,409 | 28.7 K to 26.4 K (-8.07 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 488.55 | 246 | 120,183 | 25,771 | 26 K to 25.8 K (-0.95 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 3,000 | 818,100 | 28,726 | 25.7 K to 28.7 K (+11.66 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 487.29 | 91 | 44,343 | 26,017 | 26.1 K to 26 K (-0.35 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 488.20 | 1,162 | 567,288 | 25,726 | 26.9 K to 25.7 K (-4.32 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 486.66 | 78 | 37,959 | 26,108 | 26.2 K to 26.1 K (-0.30 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 1,500 | 409,050 | 26,888 | 25.4 K to 26.9 K (+5.91 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 485.63 | 62 | 30,109 | 26,186 | 26.2 K to 26.2 K (-0.24 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 488.22 | 1,549 | 756,253 | 25,388 | 26.9 K to 25.4 K (-5.75 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 484.96 | 22 | 10,669 | 26,248 | 26.3 K to 26.2 K (-0.08 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 2,000 | 545,400 | 26,937 | 24.9 K to 26.9 K (+8.02 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 483.51 | 139 | 67,208 | 26,270 | 26.4 K to 26.3 K (-0.53 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 488.22 | 1,936 | 945,194 | 24,937 | 26.9 K to 24.9 K (-7.20 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 492.05 | 2,317 | 1,140,080 | 26,409 | 28.7 K to 26.4 K (-8.07 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 2,500 | 681,750 | 26,873 | 24.4 K to 26.9 K (+10.26 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 3,000 | 818,100 | 28,726 | 25.7 K to 28.7 K (+11.66 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 493.08 | 156 | 76,920 | 24,373 | 24.5 K to 24.4 K (-0.64 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 488.20 | 1,162 | 567,288 | 25,726 | 26.9 K to 25.7 K (-4.32 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 492.61 | 64 | 31,527 | 24,529 | 24.6 K to 24.5 K (-0.26 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 1,500 | 409,050 | 26,888 | 25.4 K to 26.9 K (+5.91 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 490.70 | 87 | 42,691 | 24,593 | 24.7 K to 24.6 K (-0.35 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 488.22 | 1,549 | 756,253 | 25,388 | 26.9 K to 25.4 K (-5.75 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 489.46 | 61 | 29,857 | 24,680 | 24.7 K to 24.7 K (-0.25 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 2,000 | 545,400 | 26,937 | 24.9 K to 26.9 K (+8.02 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 488.77 | 23 | 11,242 | 24,741 | 24.8 K to 24.7 K (-0.09 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 488.22 | 1,936 | 945,194 | 24,937 | 26.9 K to 24.9 K (-7.20 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 486.27 | 23 | 11,184 | 24,764 | 24.8 K to 24.8 K (-0.09 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 2,500 | 681,750 | 26,873 | 24.4 K to 26.9 K (+10.26 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 484.14 | 1 | 484 | 24,787 | 24.8 K to 24.8 K (0.00 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 493.08 | 156 | 76,920 | 24,373 | 24.5 K to 24.4 K (-0.64 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 481.91 | 87 | 41,926 | 24,788 | 24.9 K to 24.8 K (-0.35 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 492.61 | 64 | 31,527 | 24,529 | 24.6 K to 24.5 K (-0.26 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 479.50 | 75 | 35,963 | 24,875 | 25 K to 24.9 K (-0.30 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 490.70 | 87 | 42,691 | 24,593 | 24.7 K to 24.6 K (-0.35 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 478.97 | 23 | 11,016 | 24,950 | 25 K to 25 K (-0.09 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 489.46 | 61 | 29,857 | 24,680 | 24.7 K to 24.7 K (-0.25 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 488.77 | 23 | 11,242 | 24,741 | 24.8 K to 24.7 K (-0.09 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 486.27 | 23 | 11,184 | 24,764 | 24.8 K to 24.8 K (-0.09 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 484.14 | 1 | 484 | 24,787 | 24.8 K to 24.8 K (0.00 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 481.91 | 87 | 41,926 | 24,788 | 24.9 K to 24.8 K (-0.35 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 479.50 | 75 | 35,963 | 24,875 | 25 K to 24.9 K (-0.30 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 478.97 | 23 | 11,016 | 24,950 | 25 K to 25 K (-0.09 %) |